A Master Protocol for the Multi-Cohort Phase 1/2 Study of DCC-3116 in Combination with Anticancer Therapies in Participants with Advanced Malignancies

Brief description of study

This study is testing a medicine called DCC-3116 along with other cancer treatments for patients with advanced malignancies. The study team split the study into different parts, each looking at how well DCC-3116 works with a different treatment. First, they will try different doses of DCC-3116 to see which one is has fewest side effects when combined with the other drug. The study team will start with a few people and adjust the dose based on how safe (having few side effects) it is. Then, if it's safe, they move to the next part where they test it on more people. They want to find the best dose that works well without causing too many side effects.




If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.